Cytokinetics Sees Omecamtiv Potential In Certain Heart Failure Patients

The Company And Amgen Continue To Analyze GALACTIC-HF Results

 
• By Mandy Jackson
  
Autumn red leaf with cut heart in a hand - Image
Cytokinetics highlighted a greater benefit from omecamtiv mecarbil treatment in patients with lower LVEF • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D